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Abstract
Background: Liver fibrosis is a middle stage in the course of chronic Hepatitis B virus (HBV) infection, which will
develop into cirrhosis and eventually hepatocellular carcinoma (HCC) if not treated at the early stage. Considering
the limitations and patients’ reluctance to undergo liver biopsy, a reliable, noninvasive diagnostic system to predict
and assess treatment and prognosis of liver fibrosis is needed. The aim of this study was to identify biomarkers for
early diagnosis of HBV related liver fibrosis.
Method: Plasma samples from 7 healthy volunteers and 27 HBV infected patients with different stages of fibrosis
were selected for 2-DIGE proteomic screening. One-way ANOVA analysis was used to assess differences in protein
expression among all groups. The alteration was further confirmed by western blotting. Plasma levels of 25
serological variables in 42 healthy volunteers and 68 patients were measured to establish a decision tree for the
detection of various stages fibrosis.
Result: The up-regulated proteins along with fibrosis progress included fibrinogen, collagen, macroglobulin,
hemopexin, antitrypsin, prealbumin and thioredoxin peroxidase. The down-regulated proteins included
haptoglobin, serotransferrin, CD5 antigen like protein, clusterin, apolipoprotein and leucine-rich alpha-2-
glycoprotein. For the discrimination of milder stage fibrosis, the area under curve for Prx II was the highest. Four
variables (PT, Pre, HA and Prx II) were selected from the 25 variables to construct the decision tree. In a training
group, the correct prediction percentage for normal control, milder fibrosis, significant fibrosis and early cirrhosis
was 100%, 88.9%, 95.2% and 100%, respectively, with an overall correct percent of 95.9%.
Conclusion: This study showed that 2-D DIGE-based proteomic analysis of the plasma was helpful in screening for
new plasma biomarkers for liver disease. The significant up-expression of Prx II could be used in the early diagnosis
of HBV related liver fibrosis.
Background
Liver fibrosis is a middle stage in the course of chronic
HBV infection, which will develop into cirrhosis and
eventually hepatocellular carcinoma (HCC) if not treated
at the early stage. The risk of developing cirrhosis
depends on the degree of fibrosis (stage) and the degree
of inflammation and necrosis (grade) in liver [1,2].
Although liver biopsy is currently recommended as the
gold standard method of staging fibrosis in patients with
chronic HBV, it has several disadvantages such as poor
patient compliance, sampling error, limited usefulness
for dynamic surveillance and follow-up. Considering
these limitations and patients’ reluctance to undergo a
liver biopsy, there is a need for the development of
novel noninvasive techniques to detect early liver
damage. Several clinical studies have attempted to iden-
tify serological markers that rely on the measurement of
substances participating in the generation of the liver
extra cellular matrix. The current applications include
hyaluronic acid (HA) [3,4], type IV collagen (CIV) [4],
N-terminal propeptide of type III procollagen
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loproteinases [6], and transforming growth factor beta
[7]. Although some of these markers have shown pro-
mise for the detection of advanced fibrosis, their sensi-
tivities for detecting milder fibrosis are generally poor.
Therefore, a reliable, noninvasive diagnostic system to
predict and assess treatment and prognosis of liver
fibrosis is needed.
The biomarkers mentioned above have been identified
through a candidate approach (i.e. derived from knowl-
edge of basic biology and pathophysiology insights).
With recent advances in genomics and proteomics,
biomarkers can now be identified by discovery (or
hypothesis generation) strategies that are not limited by
our existing biological knowledge. By comprehensively
examining different protein expression profiles between
normal and pathological or drug treated samples, pro-
teomics may provide information on new biomarkers,
disease associated targets and the process of pathogen-
esis. This technique has been extensively employed to
investigate cancers and other diseases [8-17].
2-DE is a powerful technique capable of resolving sev-
eral thousand proteins based on their isoelectric points
in the first dimension and their sizes in the second
dimension [18]. A fundamental improvement was the
development of 2-D fluorescent difference in-gel electro-
phoresis (DIGE) [19], which has the ability to analyze
multiple protein samples within one gel. This is
achieved through covalent modification of each protein
with structurally similar but spectrally distinct fluor-
phores (CyDye2, CyDye3, and CyDye5). On each gel,
two samples and an internal standard comprising an
equal amount of each sample within the study can be
examined. This process reduces the gel-to-gel variation
and allows more accurate and sensitive proteomic quan-
tization [20,21].
In the present study, we employed the DIGE technol-
ogy to identify plasma profiles of liver fibrosis-related
proteins, and the further confirmation with western
blotting and ELISA showed that Prx II was better than
t h ec u r r e n ta v a i l a b l em a r k e rs in detecting milder fibro-
sis. The present findings demonstrate that proteomics is
a powerful approach for the molecular characterization
of liver fibrosis progression and the identification of
novel markers for the diagnosis of liver fibrosis.
Methods
Human Samples
Plasma samples of 49 healthy volunteers and 95 patients
with chronic hepatitis B virus infection were collected
between 2004 and 2005 from Zhongshan Hospital,
Shanghai and State Key Laboratory of Proteomics, Beijing
Proteome Research Center, Beijing, with the approval of
the Ethical Committee at Fudan University. In screening
study, subjects were restricted to patients having the
same G3 grade inflammation (moderate piecemeal necro-
sis in portal with severe focal cell damage in lobule) to
minimize unrelated variables and six groups (healthy,
S1-S4 fibrosis and cirrhosis) were enrolled (Table 1). In
validation study, four groups (healthy, milder fibrosis
(S1), significant fibrosis (S2 and S3), early cirrhosis (S4))
were enrolled to facilitate data analysis (Table 2).
All patients were measured for HBsAg, HBeAg and
HBcAg for sure of anti-HBV positive. All patients were
HBV-DNA positive (bDNA Assay 3.0, Bayer, Leverkusen).
Patients with other hepatitis virus (HAV, HCV, HEV)
infection, other liver diseases, HIV co-infections, and other
malignomas or antiviral treatment were excluded. Liver
biopsies were obtained from all patients. All samples
ranged from 1.5 to 2.0 cm long, more than 1.0 mm thick
and included at least 10 portal tracts. Classification of the
fibrosis stages and inflammation grades was done accord-
ing to Scheuer et al. [22]. The results of biopsy were inter-
preted by two pathologists independently.
Preparation of plasma samples
Blood samples were collected in sodium heparin coated
plastic tubes for the preparation of plasma. After centri-
fuged at 4,000 g for 10 min, the supernatant plasma were
divided and stored in aliquots at -80°C until analysis.
S a m p l e sw e r et h a w e do n l yo n c ef o rt h es t u d y .B e f o r e
2-DE, plasma was pretreated to deplete albumin and IgG
with the ProteoExtract Albumin/IgG Removal Kit
(Calbiochem, Darmstadt, Germany) and desalted with
the ProteoExtract Protein Precipitation Kit (Calbiochem,
Darmstadt, Germany). All experiments were done
according to the manufacture’s instruction. Samples were
dissolved in 100 μL of the DIGE lysis buffer (8 M Urea,
4% w/v CHAPS and 30 mM Tris) and adjusted to pH 8.5.
Protein content was determined using the modified
method of Bradford.
DIGE Electrophoresis
For screening study, samples in the same group were
pooled to decrease the individual differences. The same
group of sample was labeled with either CyDye3 or
CyDye5 and ran in two different gels to eliminate the
effect of dyes. 50 μg protein of each group was labeled
with 0.8 μL of CyDye3 or CyDye5 DIGE fluors minimal
dyes (400 μM), respectively. After 30 min, the incuba-
tion was stopped by adding 1 μLo f1 0m Ml y s i n e .T h e
labeled samples were further diluted with an equal
volume of the 2× sample buffer containing 8 M urea,
4% w/v CHAPS, 2% DTT, and 2% Pharmalyte pH3-10.
The internal standard included 8.33 μgo fe a c hg r o u p
(6 groups in total) labeled with CyDye2. Two different
groups (CyDye3 and CyDye5) and the internal standard
(CyDye2) were run per gel. The three labeled samples
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Page 2 of 13were mixed and the volume was adjusted to 350 μL with
rehydratation buffer containing 8 M urea, 4% w/v
CHAPS, 13 mM DTT, and 1% (v/v) IPG ampholytes pH
3-10. All gels, six in total, were processed and analyzed
simultaneously. The first dimension was carried out on
an IPGphor system (Amersham Biosciences) using pH3-
10 IPG gel strips of 24 cm. The IEF was performed at
20°C under the following conditions: 12 h at 50 V; 30
min at 250 V; 30 min at 500 V; 1 h at 1000 V; 1 h at
2000 V; 1 h at 4000 V; 2 h at 8000 V and held at 8000
V until the total Vhr reached 80000 Vhr. After isoelec-
tric focusing, the IPG strips were equilibrated for
10 min in a reduction buffer (6 M urea, 30% (v/v) gly-
cerol, 0.5% w/v DTT, and 2% (m/v) SDS in 0.05 M Tris-
HCl buffer, pH8.8) and subsequently alkylated for 10
min in an alkylation buffer containing 6 M urea, 30%
(v/v) glycerol, 4.5% (w/v) iodoacetamide, and 2% (w/v)
SDS in 0.05 M Tris-HCl buffer, pH8.8. The second
dimensional separation was carried out on the custom-
made 12% SDS-polyacrylamide gels and a Hoefer DALT
electrophoresis system (Amersham Biosciences).
Gel Image and Data Analysis
The gels were scanned using the Typhoon 9410 laser
scanner (Amersham Biosciences) at three different set-
tings (CyDye2, blue laser 488 nm and 520 bp 40 filter;
CyDye3, green laser 532 nm and 580 bp 30 filter;
CyDye5, red laser 633 nm and 670 bp 30 filter). Three
images per gel were obtained (18 in total). The scanned
images were analyzed using DeCyder 6.5 (Amersham
Biosciences). Spots were automatically detected and
visually checked for undetected or incorrectly detected
spots. The protein spots detected in each image were
automatically linked among the three images per gel. All
gels were matched to a digitized reference gel, contain-
ing all the protein spots present in all six internal stan-
dard images. The intensity levels per image were
normalized by dividing the spot volume through the
total intensity of all the spots in the image and multiply-
ing it by the average of the total spot intensity of all
18-gel images. Subsequently, the CyDye3 and CyDye5
labeled spot volumes were divided by the spot volume
of the corresponding protein spot in the internal stan-
dard (CyDye2) image. The differences in spot ratios
were analyzed by one-way ANOVA analysis and the
Student’s t test (assuming normal distributions and
equal variance). One-way ANOVA was performed for
the parameter of “liver fibrosis”.T h eP value cut-off for
ANOVA was 0.05. The proteins, found to be significant
in the first step, were further analyzed with the t test
between each paired groups. The P value cut-off for the
t test was 0.05, and the fold change was 1.5.
In-gel Digestion and MALDI-TOF MS
After scanning, the gel was stained by the MS accommo-
dated silver staining method. For each gel spot, a biopsy
punch was speared (Amersham Biosciences) and trans-
ferred to a 1.5 mL siliconikzed Eppendorf tube. Sub-
sequently, the transferred gel spots were destained in a
destaining solution (100 mM Na2S2O3 and 30 mM K3Fe
(CN)6, V/V, 1:1). The destained gel slices underwent pre-
reduction using 100% acetonitrile (HPLC grade), and gel
slices were dried in a Speed-Vac. After dried, gel slices
w e r ei n c u b a t e da t3 7 ° Cf o r1 2 - 1 6hi na nA B Cb u f f e r
(50 mM ammonium bicarbonate, pH8.0) containing
0.1 mg/mL sequencing grade modified trypsin (Promega
Biosciences, San Luis Obispo, CA). Peptide samples were
mixed at a ratio of 0.5 μL matrix (R-cyano-4-hydroxytran-
scinnamic acid) and 0.5 μL sample, loaded onto a 96×2
samples plate (Corning, P/N V700813), and crystallized.
The crystallized samples were analyzed using an Applied
Biosystems 4700 Proteomics Analyzer. In addition, tryp-
sin-digested myglobin was used as an external standard
for the mass calibration. PMF and sequence data were
matched by searching the Swiss-Prot database using the
MASCOT engine (Matrix Science).
Western blot analysis
For Western blot analysis, undepleted plasma proteins
(20 μg) were loaded onto each lane, size fractionated by
Table 1 Clinical features of all the subjects for screening study
Healthy G3S1 G3S2 G3S3 G3S4 Cirrhosis
Number 7 5 5 5 7 5
Age (Mean ± SD) 33.3 ± 9.1 35.8 ± 12.0 34.4 ± 14.3 34 ± 10.4 38.5 ± 15.1 43.3 ± 10.1
Gender (Male/Female) 7/0 4/1 4/1 4/1 6/1 4/1
Table 2 Clinical features of all the subjects for validation study
Healthy Milder fibrosis Significant fibrosis Early Cirrhosis
Number 42 24 32 12
Age (Mean ± SD) 32.9 ± 9.2 37.4 ± 12.4 34.4 ± 11.7 38.5 ± 14.4
Gender (Male/Female) 42/0 22/2 28/4 10/2
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Page 3 of 13SDS-PAGE, transferred to PVDF membrane (Amersham
Pharmacia Biotech), and blocked with PBS/5% skim
milk/0.01% Tween 20 for 30 min at room temperature.
Primary polyclonal antibodies (Abcam) diluted accord-
ing to the manufacture’s instructions in a blocking buf-
fer were added, with subsequent incubation for 1 h with
horseradish peroxidase-conjugated secondary antibodies
(Abcam). Samples were washed and developed with
ECL-Plus (Amersham Pharmacia Biotech).
Serological analysis
The plasma levels of Prx II, CLU, HP, Apo AI, LN, CIV
and PIIIP were detected by the double antibody sandwich
ELISA assay according to the published method [23]. All
antibodies used are from Abcom, Santa Cruz or Abnova.
ELISA absorbance at 450/570 nm was measured to ana-
lyze the plasma protein levels semi-quantitatively. The
plasma levels of HA were detected by RIA with the HA
test kit, following the manufacture’si n s t r u c t i o n s .O t h e r
clinical biochemical tests were done as a routine work in
our laboratory on Hitachi 7600 Biochemistry Auto analy-
zer (Hitachi, Japan). Two independent researchers
from our group performed all analyses blinded and in
duplicate.
Statistical Analysis
The SPSS 13.0 (SPSS Inc., Chicago, IL) was used to per-
form all statistical comparisons. All comparisons were
two-tailed, and a P value < 0.05 was considered signifi-
cant. Independent sample t-tests were used to analyze
protein plasma differences among the various groups.
ROC curves and AUCs were calculated, with 95% CIs.
Classification tree was developed and the growing
method is CHAID with a significant level of 0.05 for
both splitting and merging.
Results
Quantitative comparison and identification of protein
spots on DIGE gels
To smooth intrinsic individual differences and enhance
common characteristic traits only related to disease sta-
tus, plasma samples from individuals in the same group
were pooled together for the analysis. The same group
of sample was labeled with either CyDye3 or CyDye5
and ran in two different gels (Additional file 1, Table
S1). Dye swap images of each sample were acquired and
analyzed to confirm the reproducible spot pattern with
both dyes (Additional file 1, Figure S1). The 2-DE DIGE
images of the samples of different groups labeled with
different cyanine dyes were obtained by fluorescence
scanning (Figure 1). The 2-D DIGE images were ana-
lyzed by DeCyder 5.0 to objectively estimate the abun-
dance of proteins in each sample and to generate
quantitative data. In total, 812 protein spots were auto-
detected. Based on the threshold of |ratio| ≥ 1.5 and P ≤
0.05 (one-way ANOVA), the software detected 30 pro-
t e i ns p o t st h a ts h o w e das i g n i f i c a n tc h a n g ea m o n gv a r -
ious groups (Figure 1 and Table 3). Figure 2 and 3
showed the identification of Prx II and CLU, respec-
tively. Identification of Prx II by MALDI-TOF MS/MS
i ss h o w ni nA d d i t i o n a lf i l e2 ,F i g u r eS 2 .T h er a wM S
data may be downloaded from the ProteomeCommons.
org Tranche network using the following hash: TIa/
TaABaUPU2yCPt/TxF8XDiKybQOSEqzWw76bpSSYwh-
meMym9wDrfh+D4HYSudr1P3l9LQoH3RtcORcGfoaD-
vEh5wAAAAAAABCjQ==. The URL of this dataset is
https://proteomecommons.org/dataset.jsp?i=TIa%2FTaA-
BaUPU2yCPt%2FTxF8XDiKybQOSEqzWw76bpSSYwh-
meMym9wDrfh%2BD4HYSudr1P3l9LQoH3RtcORcG
foaDvEh5wAAAAAAABCjQ%3D%3D, and of data
download is https://proteomecommons.org/tranche/
data-downloader.jsp?h=TIa%2FTaABaUPU2yCPt%
2FTxF8XDiKybQOSEqzWw76bpSSYwhmeMym9wDrfh
%2BD4HYSudr1P3l9LQoH3RtcORcGfoaDvEh5wAA
AAAAABCjQ%3D%3D.
Western blot analysis for Prx II and CLU in plasma
To confirm the differential expression of Prx II, western
blotting analysis was also performed using polyclonal
antibodies against Prx II (Figure 4A). Because of the
huge diversity of protein concentration in plasma
among individuals, we did not normalize the result of
western blot with a house-keeping protein as usual.
Instead, we analyzed the expression of CLU from the
same lane of each sample to avoid errors in sample
loading and membrane transferring. As expected, the
changes of both proteins were similar to that of DIGE
result (Figure 4B,C), Compared to normal plasma, Prx II
showed to be highly present in all stage of fibrosis
plasma, although the up-regulation of Prx II was with-
drawn at S3 stage. The presence of CLU showed to
decrease continuously with the progress of fibrosis.
Thus, the up-expression of Prx II was reliable.
Measurement of Plasma Levels of Prx II and HA
We observed a significantly increased level of plasma Prx
II among the milder fibrosis patients (0.9033 ± 0.2925,
n = 24) compared with that among the normal controls
(0.5176 ± 0.1672, n = 42, P < 0.01). The plasma level of
Prx II in the significant fibrosis (0.6681 ± 0.2090, n = 32)
and early cirrhosis (0.8083 ± 0.2081, n = 12) were reduced
compared to that in the early stage, but still higher than
the normal controls (Figure 5A). We observed a signifi-
cantly elevated level of plasma HA among the early cirrho-
sis patients (median = 561.9317 ± 183.0116, n = 12)
compared to normal controls (median = 91.7035 ±
60.3199, n = 38, P < 0.01), milder fibrosis patients
(125.8983 ± 93.3860, n = 24, P < 0.01) and significant
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Page 4 of 13fibrosis patients (150.6675 ± 108.6073, n = 32, P < 0.01)
(Figure 5B).
Clinical diagnosis of 25 serological analysis markers
Twenty-five serological analysis markers, including 4 dif-
ferential proteins found by 2D-DIGE, 4 clinical plasma
fibrosis markers and 17 serological biochemical markers
were screened for their diagnosis values to various stages
of fibrosis. Table 4 shows the areas under curves (AUCs)
of discriminatory values of receiver operating characteris-
tic (ROC) analysis of 25 serological markers to normal,
milder fibrosis, significant fibrosis and early cirrhosis. For
the discrimination of milder fibrosis, the area under
curve (AUC) of Prx II was the largest (0.872 ± 0.090,
Mean ± SD), higher than other 24 markers (0.148 ±
0.076~0.733 ± 0.098, Mean ± SD). For significant fibrosis,
the AUC of CIV was the largest (0.799 ± 0.013), higher
than other 24 markers (0.237 ± 0.076~0.750 ± 0.098,
Mean ± SD). For early cirrhosis, the AUC of HA was the
largest (1.000 ± 0.013), higher than other 24 markers
(0.100 ± 0.076~0.907 ± 0.098, Mean ± SD). An AUC over
0.5 means the marker can be used for clinical diagnosis.
The higher the AUC is, the more useful the marker may
be. Unlike HA and CIV, which were useful for significant
fibrosis and early stage cirrhosis diagnostician, Prx II was
more efficient to milder fibrosis diagnostician.
For differentiation between various grades fibrosis, four
variables (PT, Pre, HA and Prx II) were selected by SPSS
software from the 25 variables to construct a decision tree
(Figure 6). In a training group, 73 samples were first
divided into three groups by marker “PT” (cutoff value =
12.00, 13.60 and 14.70, respectively): normal (25/25) &
milder fibrosis (10/18), milder (6/18) & significant fibrosis
(11/21), significant fibrosis (10/21) & early cirrhosis (9/9).
The normal & milder fibrosis group was then correctly
classified by marker “Pre” (cutoff value = 0.23); the milder
& significant fibrosis group was then correctly classified by
marker “Prx II” (cutoff value = 0.80); the significant fibro-
sis & early cirrhosis group was then classified by marker
“HA” (cutoff value = 381.74) and all the early cirrhosis
samples (9/9) were correctly classified. The correct predic-
tion percentage of the algorithm for normal control,
milder fibrosis, significant fibrosis and early cirrhosis was
100%, 88.9%, 95.2% and 100%, respectively. The algorithm
was further validated by a test group of 37 samples, and
the correct prediction percentage for normal control,
milder fibrosis, significant fibrosis and early cirrhosis was
100%, 100.0%, 88.9% and 100%, respectively (Table 5).
Figure 1 False-colored DIGE gel image of plasma proteins from normal and patient groups. Cy2 (blue) image of proteins from internal
standard plasma; Cy3 (green) and Cy5 (red) image of proteins from plasma of different groups. The overlay images showed white spots containing
proteins that have equal expression levels in each two group samples, red spots containing proteins with a higher expression and green spots
containing proteins with a lower expression in the progressive phase of fibrosis. Spots for which the volume |ratio| ≥ 1.5 (t test) and P ≤ 0.05 (one-
way ANOVA) based on DeCyder software analysis were identified by MS. In some cases, different spots were identified as the same protein.
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Plasma proteins are quite reflective of the overall profile
in humans. It is estimated that as many as 10,000 pro-
teins are present within human plasma, many of which
are secreted or shed by cells during different physiology
or pathology processes [24]. Moreover, instead of tissue,
the utility of plasma to classify the disease state would
have great advantages in that the plasma is easy to col-
lect, the procedure is minimally invasive, and samples
can be collected repeatedly. Therefore, considerable
efforts have been made to discover plasma biomarkers
for clinical purposes [25,26].
Recently, proteomics, a powerful strategy which can
provide the global information of new biomarkers,
Table 3 List of identified proteins
a
Spot
No.
b)
Protein ID
c) Procession
No.
d)
Protein
Score
e)
C.I.%
f) Ion
Score
e)
C.I.%
f) Peptide MW(kDa)
g)
theoretical/
observed
pI
g)
theoretical/
observed
Appearance
h) P
value
I)
1 a-2
macroglobulin
P01023 341 100 185 100 34 163/90 6/5.6 12(18) 0.03
2 a-2
macroglobulin
P01023 341 100 185 100 34 163/90 6/5.7 12(18) 0.03
3 a-2
macroglobulin
P01023 341 100 185 100 34 163/90 6/5.8 12(18) 0.03
4 a-2
macroglobulin
P01023 341 100 185 100 34 163/90 6/5.9 12(18) 0.03
5 Serotransferrin P02787 297 100 119 100 33 77/80 6.81/6.5 15(18) 0.012
6 Serotransferrin P02787 78 99.992 37 99.6 13 77/80 6.81/6.5 12(18) 0.015
7 Hemopexin P02790 120 100 44 99.996 19 52/60 6.55/4.5 15(18) 0.021
8 Hemopexin P02790 178 100 80 100 19 52/60 6.55/4.5 15(18) 0.025
9 LRG P02750 108 100 55 100 15 34/34 5.66/5.4 18(18) 0.029
10 LRG P02750 199 100 134 100 18 34/34 5.66/5.4 18(18) 0.041
11 Fibrogen g
chain
P02679 146 100 40 99.987 18 50/50 5.61/5.9 15(18) 0.03
12 a-1 antitrypsin P01009 76 99.986 33 99.942 11 47/56 5.37/5.2 12(18) 0.011
13 APO-AIV P06727 143 100 41 99.991 15 45/45 5.28/5.2 18(18) 0.021
14 APO-AIV P06727 143 100 41 99.991 15 45/45 5.28/5.2 18(18) 0.021
15 Fibrogen b
chain
P02675 341 100 150 100 36 56/46 8.54/5.5 15(18) 0.021
16 Clusterin P10909 144 100 86 100 17 52/40 5.89/5.0 18(18) 0.013
17 Clusterin P10909 130 100 71 100 17 52/39 5.89/5.2 18(18) 0.013
18 Clusterin P10909 74 99.98 59 100 12 52/35 5.89/5.3 18(18) 0.013
19 Clusterin P10909 127 100 74 100 17 52/34 5.89/5.4 18(18) 0.016
20 APO-A1 P02647 255 100 87 100 28 31/28 5.56/5.2 18(18) 0.013
21 APO-A1 P02647 364 100 107 100 33 31/28 5.56/5.3 18(18) 0.013
22 APO-A1 P02647 214 100 21 99.305 25 31/28 5.56/5.3 18(18) 0.021
23 APO-A1 P02647 404 100 113 100 39 31/28 5.56/5.4 18(18) 0.021
24 Thioredoxin
peroxidase 1
P32119 263 100 143 100 16 22/21 5.66/5.4 15(18) 0.021
25 HP-2 P00738 71 99.961 19 99.13 10 45/20 6.13/5.4 18(18) 0.0031
26 HP-2 P00737 91 100 58 100 12 38/20 6.13/5.6 18(18) 0.0051
27 HP-2 P00738 88 100 58 100 11 45/20 6.13/6.3 18(18) 0.0051
28 Prealbulmn P02766 53 97.616 25 99.732 7 16/16 5.52/5.2 18(18) 0.0067
29 Prealbulmn P02766 56 98.66 54 99.944 7 16/16 5.52/5.3 15(18) 0.0067
30 Prealbulmn P02766 127 100 64 100 10 16/16 5.52/5.6 12(18) 0.013
a) Spots for which the volume |ratio| ≥ 1.5 (t test) and P ≤ 0.05 (one-way ANOVA) based on DeCyder software analysis were identified by MALDI-TOF/TOF MS.
b) Spots referring to Figure 2.
c) Spots in the same line were identified as same protein.
d) Protein ID accessed from Swiss-Prot database by data searching.
e) Total protein score analyzed by MS and total ion score of the peptide analyzed by MS/MS.
f) Confidence of protein score and ion score.
g) Theoretical MW and pI accessed from UniProt database.
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Page 6 of 13Figure 2 Plasma Prx II levels were up-regulated with fibrosis progress. A: Magnified region of DIGE gel image of Prx II. B: The patterns of
the relative abundance alterations of Prx II in different groups. C: The MALDI-TOF MS map of Prx II, in which peptide peaks for further MS/MS
identification are labeled out with mass value and the MS/MS map of peptide 1121.71 was shown. D: The amino acid sequences of Prx II, in
which MS/MS matched peptide sequences, are underlined.
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Page 7 of 13Figure 3 Plasma CLU levels were down regulated with fibrosis progress. A: Magnified region of DIGE gel image of CLU. B: The patterns of
the relative abundance alterations of CLU in different groups. C: The MALDI-TOF MS map of CLU, in which peptide peaks for further MS/MS
identification are labeled out with mass value. D: The amino acid sequences of CLU, in which MS/MS matched peptide sequences are
underlined.
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Page 8 of 13Figure 4 Protein expressions of Prx II and CLU in plasma by Western blot analysis.A :S i n g l es a m p l e so fn o r m a la n dl i v e rf i b r o s i s .
Immunoblotting with Prx II or CLU polyclonal antibody following SDS-PAGE was performed as described in Section 2.7. The films were scanned
and the OD of each band in the film was evaluated by QuantitiOne software. B: The change of Prx II expression is similar to DIGE result (Figure 2.B).
C: The change of CLU expression is similar to DIGE result (Figure 3.B).
Figure 5 Human plasma levels of Prx II and HA. A: the plasma levels of Prx II were significantly elevated in patients with milder grade fibrosis
compared to those in normal controls. The plasma level of Prx II in the late stage fibrosis and early cirrhosis were reduced compared to that in
the early stage, but still higher than the normal controls. B: a significantly elevated HA plasma level among the early cirrhosis patients compared
to normal controls and fibrosis patients. Compared to normal:* P < 0.05, ** P < 0.01.
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Page 9 of 13disease associated targets and the process of pathogen-
esis by comprehensively examining different protein
expression profiles between normal and pathological or
drug treated samples, has been extensively employed to
investigate cancers and other diseases. However, plasma
proteome analysis is still a daunting task largely due to
abundant proteins such as albumin and IgG that consti-
tute approximately 60-97% of the total plasma proteins
[27]. Efficient depletion of abundant proteins from
h u m a np l a s m ae n a b l e st h ed e t e c t i o no fm o r ep r o t e i n s
with greater protein coverage [28]. On the other hand,
the depletion of highly abundant proteins may result in
the loss of potentially important proteins bound to them
a tt h es a m et i m e .T h em o r ek i n d so fa b u n d a n tp r o t e i n s
are depleted, the more unspecific bounded proteins may
loose [29]. Therefore, we chose to deplete albumin and
IgG to minimize the unspecific protein depletion (Addi-
tional file 3, Figure S3). Depleting these two abundant
proteins prior to the DIGE technology increased the
loading volume from 5 μLt o3 5μL (estimated raw
plasma volumes with same protein amount), and signifi-
cantly improved the detection of low abundant proteins.
Proteins, such as clusterin, hemopexin and thioredoxin
peroxidase, could be detected in the μg/mL range,
which cannot be detected by the traditional 2-DE
technology.
Pooling samples is a common way to reduce the cost
of experiments as well as to provide equivalent power of
experiments [30-32]. Since the purpose of our study is
to identify robust biomarkers related with the progress
of liver fibrosis, the differences among various groups
are more interesting than the differences between
patients within each patient group. We pooled the sam-
ples to smooth intrinsic individual differences and
enhance common characteristic traits only related to
disease status. It is also true that pooling samples may
eliminate the number of biological replicates. Therefore,
we analyzed protein levels in a larger population by
ELISA to make up the disadvantages of pooling samples.
In this study, the albumin and IgG depletion strategy
prior to 2-D DIGE was applied to enrich the low-
abundant proteins in human plasma. By the 2-D DIGE,
several proteins with significant alterations related with
fibrosis progress were found. The up-regulated proteins
were identified as fibrogen, collagen, macroglobulin,
hemopexin, antitrypsin, prealbumin and thioredoxin
peroxidase. The down-regulated proteins were haptoglo-
bin, serotransferrin, CD5 antigen like protein, clusterin,
apolipoprotein and leucine-rich alpha-2-glycoprotein
(LRG). The biological functions of these proteins can be
summarized into four groups: (A) Generation and
degradation of extra cellular matrix (ECM), such as
fibrogen, collagen and macroglobulin [33]; (B) Acute
phase reaction and immunity protection, such as anti-
trypsin, prealbumin, LRG [34] and CD5 antigen-like
protein; (C) Oxygenation and cell apoptosis, such as
clusterin [35] and thioredoxin peroxidase [36,37]; (D)
Transport and metabolism, such as apolipoprotein, hap-
toglobin, hemopexin and serotransferrin. As expected,
proteins related to the generation of extra cellular
matrix had the same alteration pattern of increase,
which is in accordance with the progress of fibrosis.
Proteins with the function of transport and metabolism
had the same alteration pattern of decrease, which
implied the dysfunction of the liver with the develop-
ment of fibrosis. Most of the proteins found to be up-
or down regulated were described in prior papers, which
imply the reliability of our study design and the DIGE
technology.
Table 4 Areas under curve of ROC analysis of 25
serological markers
State Variable
b)
Test
Variable
a)
Normal Milder
fibrosis
Significant
fibrosis
Early
cirrhosis
A 0.852 0.433 0.237 0.263
A/G 0.898 0.398 0.244 0.171
AFP 0.356 0.338 0.666 0.857
AKP 0.325 0.552 0.522 0.876
Apo AI 0.508 0.423 0.565 0.468
AST/ALT 0.818 0.148 0.247 0.692
CB 0.282 0.546 0.569 0.896
CHE 0.695 0.441 0.468 0.100
C-IV 0.136 0.470 0.799 0.894
CLU 0.290 0.527 0.738 0.453
G 0.119 0.610 0.713 0.878
HA 0.314 0.478 0.549 1.0000
HB 0.613 0.452 0.404 0.511
HP 0.329 0.601 0.603 0.537
LN 0.419 0.534 0.589 0.438
Prx II 0.216 0.872 0.500 0.577
PIIIP 0.475 0.512 0.498 0.558
PLT 0.512 0.426 0.372 0.226
Pre 0.543 0.506 0.568 0.263
PT 0.098 0.242 0.528 0.855
rGT 0.266 0.733 0.640 0.872
TB 0.3750 0.587 0.551 0.907
TC 0.688 0.424 0.294 0.637
TG 0.541 0.454 0.502 0.466
WBC 0.265 0.549 0.750 0.488
a) Abbreviations used for test variables
A: albumin; A/G: albumin/IgG; AFP: alpha fetal protein; AKP: alkaline
phosphotase; AST: Aspartate aminotransferase; ALT: Alanine Aminotransferase;
CB: Combined bilirubin; CHE: cholinesterase; C-IV: collagen type IV; CLU:
clusterin; G: IgG; HA: Sodium Hyaluronate; HB: hemoglobin; HP: Haptoglobin;
LN: laminin; Prx II: thioredoxin peroxidase 2; PIIIP: pre-collagen peptide type III;
PLT: platelets; Pre: prealbumin; PT: prothrombin time; rGT: gama glutamyl
transpeptidase; TB: total bilirubin; TC: total cholesterol; WBC: white blood cells.
b) The maximal AUCs for each state are shown in bold.
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Page 10 of 13However, some of the identified proteins had different
observed MW or pI, compared to theoretical ones. This
is because that the proteins detected in plasma are
secreted proteins, which are usually smaller than the
whole protein. And the post translation modification of
proteins, either carbamidomethyl, oxidation or phos-
phorylation, will change the pI of proteins greatly.
Of the 13 identified proteins, thioredoxin peroxidase
appears to be a novel candidate as useful HBV-related
milder grade liver fibrosis marker. Large evidence shows
that in humans and animals, oxidative stress is implicated
in the resistance to HBV infection and serves as a link
between hepatic injury and fibrosis [38,39]. Thioredoxin
peroxidases, also called peroxiredoxins, are members of a
newly discovered family of peroxidases, and they effi-
ciently reduced the intracellular level of H2O2 produced
in those cells stimulated by various cell surface ligands.
The peroxiredoxin family was reported to be closely
related to various causes of liver fibrosis. They were
found to be up-regulated in liver fibrosis caused by alco-
hol exposition [40], schistosomiasis [41], drug and chemi-
cal induction [41,42]. The oxidation kinetics of all
peroxiredoxins was extremely rapid and sensitive, occur-
ring at H2O2 doses unable to affect common markers of
Figure 6 Decision tree for the differentiation of various stages fibrosis using four serological markers. Briefly, in a training group of 73
samples, samples were first divided into three groups (normal & milder fibrosis, milder & significant fibrosis, significant fibrosis & early cirrhosis)
by marker “PT” (cutoff value = 12.00, 13.60 and 14.70, respectively); The normal & milder fibrosis group was then correctly classified by marker
“Pre” (cutoff value = 0.23); the milder & significant fibrosis group was then correctly classified by marker “Prx II” (cutoff value = 0.80); the
significant fibrosis & early cirrhosis group was then classified by marker “HA” (cutoff value = 381.74) and all the early cirrhosis samples (9/9) were
correctly classified. The correct prediction percentage of the algorithm for normal control, milder fibrosis, significant fibrosis and early cirrhosis
was 100%, 88.9%, 95.2% and 100%, respectively.
Table 5 Correct percentage of prediction for various grades fibrosis
Predicted
Sample Observed normal Milder
fibrosis
Significant Early
cirrhosis
Percent
Correct (%)
Training normal 25 0 0 0 100
milder fibrosis 0 16 2 0 88.9
significant fibrosis 0 0 20 1 95.2
early cirrhosis 0 0 0 9 100
Overall Percentage 34.2 21.9 30.1 13.7 95.9
Test normal 17 0 0 0 100
milder fibrosis 0 6 0 0 100
significant fibrosis 0 2 8 1 72.7
early cirrhosis 0 0 0 3 100
Overall Percentage 45.9 21.6 21.6 10.8 91.9
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Page 11 of 13cellular oxidative stress [43]. In our research, Prx II has
shown a significant up-regulation at the milder stage
fibrosis, which indicated that it is an early protein target
of HBV induced oxidative injury. On the contrary, cur-
rent available fibrosis biomarkers, such as HA, CIV, PIIIP
and LN, rely on the measurement of substances that par-
ticipate in the generation of the liver extra cellular matrix
and thus have limited clinical application value in milder
fibrosis prediction.
As the complexity of liver fibrosis disallows any single
biomarker to guide the diagnosis, prognosis, and treat-
ment of the disease, we tried to use the tree classifica-
tion system to predict the v a r i o u sf i b r o s i ss t a g e s .
Among the 25 serological analysis markers screened,
PT, Pre, Prx II and HA were selected to construct a
decision tree. The correct prediction percentages in
both the training group and the test group were high. In
the algorithm, Pre-albumin was used to correctly classify
between normal and milder fibrosis, indicating an acute
phase reaction at the beginning of fibrosis. Prx II was
used to correctly classify between milder and significant
fibrosis, indicating an anti-oxidative stress reaction dur-
ing the progress of fibrosis. HA was used to correctly
classify between significant fibrosis and early cirrhosis,
indicating an assembling of ECM at the late stage of
fibrosis.
Conclusion
In this study, we have shown the quantitative plasma
protein profiles in various stages liver fibrosis patients,
and have found several proteins that changed signifi-
cantly during disease progression. The differential
expressed proteins have four groups of biological func-
tions, which is helpful for revealing the underlying
mechanisms of liver fibrosis. The significant up-regula-
tion of Prx II implied that it held comparable sensitivity
and specificity in the prediction of milder fibrosis, which
may be useful for early fibrosis diagnosis if validated in
other cohorts.
Additional material
Additional file 1: Experiment design of DIGE. Additional file 1
contains Table S1, in which the experiment design of DIGE is explained,
and Figure S1, in which DIGE image of sample G3S1 labeled with Cy3
and Cy5 is shown. It can be seen that the spot pattern is reproducible
with both dyes. Therefore, each sample was labeled with either Cy3 or
Cy5 and ran on two individual gels to eliminate the possible effect of
different Dyes on sample electrophoresis.
Additional file 2: Identification of Prx II by MALDI-TOF MS/MS.
Additional file 2 contains Figure S2, in which MALDI-TOF MS map of Prx
II, tandem MS/MS spectra of peptide m/z 1211.71, 1735.02 and 1864.11,
and the amino acid sequences of Prx II are shown.
Additional file 3: Effect of albumin and IgG depletion. Additional file
3 contains Figure S3, in which 2-DE gels of raw plasma and depleted
plasma are shown. It can be seen that after depletion, two most
abundant plasma proteins, albumin and IgG, are successfully removed.
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